OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.30

+4.4%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$58.80M
EPS-4.4000
P/E Ratio-0.98
Earnings Date08/11/2026

okur

Other Non-Current Liabilities

Last Annual Value

12.00K

3-Year CAGR

-94%

5-Year CAGR

%

10-Year CAGR

%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Other Non-Current Liabilities

OKUR · NASDAQ
CompanyOther Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
12.00K
-95.5%-51.4%N/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
12.23M
-23.8%147.0%N/A
125.00K
0.0%0.0%-34.4%
57.53M
N/AN/AN/A
0.00
N/AN/AN/A
8.00K
100.0%-61.7%-60.9%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.3, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.3